Acute Cardiac Safety - MEA Analysis

Ncardia’s in-house Acute Cardiac Safety service provides acute cardiac safety profiles of test compounds based on the electrophysiology of fully functional and validated human cardiomyocytes.

What are the benefits?

Fully functional model
Proven ion channel modulating effects of CiPA-reference compounds

Reproducible results
Use of fully validated and quality controlled cardiomyocytes

Label-free and non-invasive physiological assay system


Investigating the electrical activity of human induced pluripotent stem cell-derived cardiomycoytes (hiPSC-CMs) and their acute response to drugs is part of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, which aims to refine current ICH guidelines to predict clinical potential for life threatening Torsade de Pointes (TdP) tachyarrhythmia.

Ncardia is an official partner of the CiPA initiative and our cardiomyocytes were implemented by different core and non-core test sites. Our cardiomyocytes in combination with MEA platforms provide a highly relevant and predictive in vitro assay platform to study compounds’ cardiac safety profile in drug development.

*CiPA (Comprehensive in Vitro Proarrhythmia Assay) is a project driven by the Health and Environmental Science Institute (HESI) and the FDA.



Would you like to know more about our acute cardiac safety service, or any of our other services?

We're here to listen to your project plans, questions and challenges, and to co-develop a solution that fits your specifications. Please leave your details and message in the form below and we will get back to you as soon as possible.